You are here: Industry Insights > AbbVie

News List

The Coming Successor and the Ending Humira Yi/PharmaSources
March 01, 2023
On January 31, Amgen announced that its Humira (Adalimumab) biosimilar, Amjevita (adalimumab-atto), had entered into the American market officially.And Amjevita is also the first adalimumab biosimilar approved by FDA.
AbbVie's performance in 2021: a new high in total revenue, with the sales volumes of Hu-mi-ra topping USD 20 billion PharmaSources/Yi
February 22, 2022
On February 2, AbbVie announced its performance in the fourth quarter and full year of 2021, representing an annual revenue of USD 56.197 billion (+22.7%) and R&D investment of USD 7.084 billion (+8%).
FDA expands approval for AbbVie’s Skyrizi for active psoriatic arthritis Pharmaceutical-Technology
January 26, 2022
The FDA approval is based on data from two Skyrizi Phase III trials, KEEPsAKE-1 and KEEPsAKE-2.
US FDA approves drugs from AbbVie and Pfizer to treat eczema ExpressPharma
January 17, 2022
AbbVie’s Rinvoq and Pfizer’s Cibinqo have been approved to treat moderate-to-severe eczema, in patients who do not respond to previous treatment, or when use of other treatments is not recommended...
AbbVie submits applications for Upadacitinib in to US FDA and EMA ExpressPharma
January 10, 2022
In the trial study, evaluating the efficacy and safety of Upadacitinib in adult patients with nr-axSpA, Upadacitinib met its primary and most-ranked secondary endpoints.
AbbVie seeks approval for upadacitinib to treat nr-axSpA pharmaceutical-business-review
January 10, 2022
Abbvie has submitted applications to the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to obtain approvals...
Frontier Medicines Advances First Target Under Abbvie Alliance contractpharma
January 10, 2022
Continues to advance its ongoing efforts and strategic focus on difficult-to-drug protein targets.
AbbVie’s Teliso-V Granted BTD in NSCLC contractpharma
January 04, 2022
For the treatment of patients with advanced/metastatic epidermal growth factor receptor (EGFR) wild type, nonsquamous non-small cell lung cancer (NSCLC).
AbbVie seeks EMA approval for risankizumab (Skyrizi) to treat moderate to severe Crohn’s disease Pharmaceutical-Business-Review
December 02, 2021
AbbVie has sought approval from the European Medicines Agency (EMA) for risankizumab (Skyrizi, 600 mg intravenous (IV) induction and 360 mg subcutaneous (SC) maintenance therapy), to treat patients who are 16 years and above suffering with moderate to...
AbbVie, University of Chicago extend oncology research collaboration Pharmaceutical-Business-Review
November 15, 2021
AbbVie has extended a collaboration agreement with the University of Chicago until 2025 to support preclinical research in oncology.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 28 29 Next page